Rhythm Pharmaceuticals (RYTM) News Today

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a

Rhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High at $53.07

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 9,240,000 shares, a drop of 16.3% from the June 15th total of 11,040,000 shares. Based on an average daily trading volume, of 545,400 shares, the short-interest ratio is presently 16.9 days.

Vanguard Group Inc. boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 7.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,226,938 shares of the company's

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 3.8%

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.5%

Hennion & Walsh Asset Management Inc. lifted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 30.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 86,967 shares of the company's stock after buying an additional

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating t

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 4.6%

Healthcare of Ontario Pension Plan Trust Fund trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,843 shares of the company's sto

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 4.8%

Perceptive Advisors LLC grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 465.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,154,110 shares of the company's stock after purchasing an addi

Virtu Financial LLC purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 26,501 shares of the company's stock, valued at app

Commodore Capital LP lowered its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 25.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,550,000 shares of the company's stock after selling 5

Bellevue Group AG decreased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,869 shares of the company's stock after selling

TD Asset Management Inc purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 37,800 shares of the company's stock, valued at

Rafferty Asset Management LLC cut its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 121,654 shares of the company's stock after sel

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 8.2%

Artisan Partners Limited Partnership acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 271,421 shares of the company's stock, valued at approximately $12,

Clearbridge Investments LLC cut its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 50.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,158 shares of the compan

Primecap Management Co. CA reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,052,648 shares of

Victory Capital Management Inc. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 809.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,297 shares of the com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 3,984 shares of the stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $38.47, for a total value of $153,264.48. Following the completion of the sale, the insider now directly owns 30 shares of the company's stock, valued at approximately $1,154.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.